OLD National Bancorp IN Has $445,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

OLD National Bancorp IN lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,584 shares of the medical device company’s stock after selling 301 shares during the period. OLD National Bancorp IN’s holdings in DexCom were worth $445,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Valley National Advisers Inc. raised its holdings in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares during the period. MV Capital Management Inc. increased its holdings in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares during the period. Washington Trust Advisors Inc. increased its holdings in shares of DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 193 shares during the period. NBC Securities Inc. acquired a new position in shares of DexCom in the 3rd quarter valued at about $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new position in shares of DexCom in the 3rd quarter valued at about $48,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 20,321 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at $10,747,722.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at $8,304,405.66. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the sale, the executive vice president now owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The disclosure for this sale can be found here. Insiders sold 189,375 shares of company stock worth $25,530,859 over the last three months. 0.41% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on DXCM shares. Royal Bank of Canada started coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Raymond James increased their price objective on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 23rd. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Citigroup increased their price objective on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $141.40.

DexCom Stock Up 2.9 %

DXCM opened at $137.87 on Thursday. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $54.60 billion, a price-to-earnings ratio of 105.25, a P/E/G ratio of 2.30 and a beta of 1.20. The business has a 50 day moving average of $130.58 and a 200-day moving average of $117.88.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. During the same period in the prior year, the business earned $0.34 earnings per share. DexCom’s revenue for the quarter was up 26.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that DexCom, Inc. will post 1.76 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.